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Abstract
Purpose To raise awareness of Stargardt disease (STGD1) patients without fundus abnormalities.
Methods Medical records were evaluated for age at onset, initial symptoms and diagnosis, reason for delay of diagnosis, age at
STGD1 diagnosis, best-corrected visual acuity (BCVA), ophthalmoscopy, fundus photography, fundus autofluorescence (FAF),
fluorescein angiography (FA), spectral-domain optical coherence tomography (SD-OCT), full-field electroretinography (ffERG),
color vision test, and the presence of ABCA4 variants.
Results In 11.1% of our STGD1 cohort of 280 patients, no fundus abnormalities were observed at first ophthalmic consultation.
The median age at onset was 8 years (range, 1–18). There was a median delay in diagnosis of 3 years (range, 0–19) in 27 out of 31
patients, which resulted in a median age at diagnosis of 12 years (range, 7–26). Patients were misdiagnosed with amblyopia,
myopia, optic disk pathology, mental health problems, tension headache, neuritis bulbaris, and uveitis. Subtle abnormalities, such
as lipofuscin accumulation, were seen on FAF at an earlier disease stage than in ophthalmoscopy. On SD-OCT, this included a
thickened external limiting membrane. Color vision tests showed red-green insufficiency in 79% of patients. Reduced ERG
amplitudes were only present in 26% (N = 8) and a dark choroid sign in 65% of the patients. Visual acuity considerably fluctuated
in the first 5 years after onset. The majority of the patients (65%) carried a least one variant with a severe effect on ABCA4
function.
Conclusions Childhood-onset STGD1 patients were diagnosed with a delay of median 3 years. The presence of accurate
competence, equipment, and the possibility for genetic screening is required; therefore, we recommend to refer children with
visual complaints without initial fundus abnormalities to a specialized ophthalmologic center. In particular, to diagnose patients at
an early stage of disease is of increased importance with the advent of new therapeutic possibilities.
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Introduction
Stargardt disease (STGD1) is arguably the most common ret-
inal dystrophy and affects 1:10000 people worldwide [1]. This
autosomal recessive disease is caused by variants in the
ABCA4 gene that encodes for a retinal-specific ATP-binding
cassette transporter protein. Dysfunction of the ABCA4 pro-
tein leads to toxic accumulation of byproducts from the visual
cycle in the photoreceptor cell and retina pigment epithelium
(RPE), which eventually leads to irreversible damage of the
outer retinal layers [2, 3].
Up to 5962 variants in the ABCA4 gene have been identi-
fied; the specific combinations of variants in conjunction with
largely unknown modifying factors in each patient result in a
highly heterogenic phenotype [4]. Patients with STGD1 pres-
ent with progressive vision loss, which typically occurs in
young adulthood, but early and late forms have been well
recognized [5–7]. In general, the fundus picture is character-
ized by the presence of irregular yellow-white fundus flecks in
the posterior pole. During the course of the disease, macular
atrophy develops, sometimes with a Bbeaten bronze^ aspect;
in other patients, a bull’s eye pattern can be observed.
Lipofuscin accumulates in the outer retinal layers, which re-
sults in a Bdark choroid^ on the fluorescein angiogram in
approximately 80% of the patients [8–11]. In early forms with
a disease onset ≤ 10 years of age, atrophy of the macula is a
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prominent and early feature; the yellow flecks may be absent
or hardly notable [5, 12, 13]. The flecks are much more com-
mon in the classic form of STGD1 with an age of onset in the
early teens, sometimes extending beyond the vascular arcades
resulting in the fundus flavimaculatus phenotype [14, 15].
Late-onset forms of the disease are characterized by atrophy
of the retinal pigment atrophy, subtle flecks, and foveal spar-
ing [6, 16, 17].
The diagnosis of STGD1 can be challenging in early dis-
ease especially, as no apparent changes may be present on
ophthalmoscopy despite the loss of visual function [5]. This
lack of clinical signs in combination with the limited capabil-
ities for expression in young children may delay the correct
diagnosis. Not only is early identification of these patients
essential for the emotional aspect of a timely diagnosis, it is
also important in the light of emerging therapeutic options for
STGD1 disease, such as gene augmentation (trial number
NCT01367444, NCT01736592), stem cell therapy (trial num-
ber NCT01469832), and small molecule drugs (trial number
NCT02402660).
In this study, we describe—in detail—the clinical and mo-
lecular genetic findings in a group of STGD1 patients, which
presents without initial fundus abnormalities in ophthalmos-
copy. We hope that a heightened awareness avoids misdiag-
nosis, such as functional visual loss in these children and, in
worst case scenarios, years of inappropriate treatment.
Methods
Patients
The database with STGD1 patients of the Department of
Ophthalmology, Radboud University Medical Center,
(Nijmegen, the Netherlands) contains 280 patients of all ages
and disease-onset, of whom one or more ABCA4 variants
could be identified. We included 31 patients who did not show
obvious fundus abnormalities at the first presentation. This
study was approved by the Institutional Ethics Committee
and was performed in accordance with the Declaration of
Helsinki.
Clinical evaluation
We collected the clinical data from the medical records. These
included age at onset, initial symptoms, initial diagnosis and
examinations or therapy, age at STGD1 diagnosis, delay of
diagnosis and reason for this delay, number of referrals before
diagnosis, and general medical history. Age at onset was de-
fined as the first manifestation of the disease, and these symp-
toms could have been noticed by not only the patient, but also
their family members and/or the school physician. If visual
complaints of the patient were initially diagnosed due to stress
or need for attention, we used the term Bmental health issues^.
The standard ophthalmic examination included best-
corrected visual acuity (BCVA) using Early Treatment
Diabetic Retinopathy Study (ETDRS) or Snellen charts, slit-
lamp biomicroscopy, and detailed fundus examination. BCVA
was transformed into the logarithm of the minimum angle of
resolution (logMAR) for statistical analysis. For fundus pho-
tography, we used the Topcon TRC50IX (Topcon
Corporation, Tokyo, Japan). Fluorescein angiography (FA)
and cross-sectional images using spectral-domain optical co-
herence tomography (SD-OCT) centered at the macula were
obtained with the Spectralis (HRA + OCT, Heidelberg
Engineering, Heidelberg, Germany). Short-wave fundus auto-
fluorescence imaging (FAF) (λ = 488 nm, emission 500–
700 nm) was performed using a confocal scanning laser oph-
thalmoscope (Spectralis HRA +OCT or HRA2, Heidelberg
Engineering, Heidelberg, Germany). The field of view was
set at 30° × 30° or 55° × 55°, centered at the macula. For eval-
uation of color vision, we employed the Ishihara or Panel D-
15 test. Full-field electroretinography (ERG) was performed
usingDawson-Trick-Litzkow (DTL) electrodes and the RETI-
port system (Roland Consults, Stasche & Finger GmbH,
Brandenburg an der Havel, Germany). The recordings were
performed in accordance with the guidelines of the
International Society for Clinical Electrophysiology of
Vision (ISCEV) [18]. We grouped ERG results as described
by Lois et al. [19]: group 1—patients with normal ERG re-
sponses, group 2—patients with reduced photopic amplitudes
(< 5% of normal range), and group 3—patients with reduced
photopic and scotopic amplitudes (< 5% of normal range).
Genetic analyses
Genetic analysis of the ABCA4 gene was performed at the
Department of Human Genetics at the Radboud University
Medical Center using arrayed primer extension analysis
(APEX, Asper Biotech, Tartu, Estonia). If the Asper microar-
ray screening revealed only one ABCA4 variant, exon and
intron-exon boundaries were sequenced in the ABCA4 gene
to identify additional variants. All variants were confirmed
with Sanger sequencing. The following variants were defined
as severe: protein-truncating, canonical splice-site variants,
and deletions spanning at least one exon.
Statistical analysis
We used SPSS version 22.0 (IBM Corp, Armonk, NY) for
statistical data analysis, using descriptive statistics by median
and range for continuous variables and percentages for cate-
gorical variables. We employed Kaplan-Meier estimators to
analyze the interval between age at onset and age at which
four different visual endpoints were reached. These four
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points were based on the classification of visual impairment of
the World Health Organization: (near-)normal to mild visual
impairment ≥ 0.2 logMAR (≤20/32 Snellen), moderate visual
impairment ≥ 0.6 logMAR (≤ 20/80 Snellen), severe visual
impairment ≥ 1.0 logMAR (≤ 20/200 Snellen), and blindness
≥ 1.4 logMAR (≤ 20/500 Snellen).
Results
Clinical characteristics
In 31 of 280 (11.1%) STGD1 patients, no obvious fundus abnor-
malities were observed at the first ophthalmic consultation. The
group consisted of 15 males and 16 females with six siblings
from three different families and 25 isolated cases. An overview
of the clinical findings and the diagnostic process is given in
Table 1. In one third of cases, symptoms of a decreased visual
acuity were not noticed by the patient, but by the parents or a
school physician. Age at onset occurred at a median age of
8 years (range, 1–18). In 87% of the patients, there was a delay
in diagnosis: a median delay of 3 years (range, 0–19), which
resulted in a median age at diagnosis of 12 years (range, 7–26).
The main reason for delayed STGD1 diagnosis was misdiagno-
sis, in particular amblyopia treated with occlusion therapy (6
patients) and mental health issues (5 patients). The majority of
patients (94%) visited more than two hospitals before the correct
diagnosis was made. All patients were finally diagnosed with
STGD1 in tertiary referral centers. The first fundus abnormalities
were observed at a median time of 3 years (range, 0.5–16) after
first symptoms. These included central retinal pigment epitheli-
um (RPE) alterations (43%), bull’s eye maculopathy (33%), and/
or parafoveal flecks (24%). Once these features had been ob-
served, STGD1 was generally diagnosed relatively quickly in
the majority of patients (median, 0.7 years, range, 0.1–3).
We could retrieve the BCVA at the first ophthalmic visit in 21
out of 31 patients; the median BCVA at that time was 20/32
Snellen (20/20–20/400). The median interval and 95% confi-
dence interval (CI) between the age at onset and decline in
BCVA to mild, moderate, and severe visual impairment and
blindness was 1 year (95% CI, 0.0–2.25), 4 years (95% CI,
3.1–4.9), and 12 years (CI 95% 7.8–16.2). One patient reached
blindness 34 years after the first symptoms of onset at age 9. In
many patients, the visual acuity findingswere quite variable early
in the course of the disease as shown in Fig. 1.
In 29 out of 31 patients, fundus flecks were eventually
noticed at a median time of 3.5 years (range, 0.1–16.5) after
the initial ophthalmic consultation. In 17 patients (59%), sub-
tle parafoveal flecks could be seen; in 5 patients (17%), flecks
were noticed within the vascular arcades; and in 7 patients
(24%), flecks extended to the periphery. In 2 patients, no fun-
dus flecks were reported at any time during the course of the
disease (follow-up time, 1 and 10 years).
In 23 of 31 patients, the first SD-OCT was performed at
9 years (range, 0.1–24) after disease onset. No SD-OCT scans
were performed in the remaining 8 patients. All OCT scans
showed abnormalities by disorganized or absent RPE. A
thickened external limiting membrane (ELM) was seen in 2
patients (0.5 and 1 year after disease onset). A dark choroid
was observed in 15 of 23 (65%) patients in whom FA was
performed. In 22 patients, the first FAF was performed
3.5 years (0.5–24) after onset. No atrophy was seen (median,
1 year after onset) in 5 patients, (peri)foveal atrophy in 9
(median, 4 years after onset), atrophy within the vascular ar-
cades in 7 (median, 15 years after onset), and panretinal atro-
phy (15 years after onset) in 1. In 4 patients, abnormalities
were seen on FAF, but were missed on ophthalmoscopy.
The first ERG was performed 2 years (0.1–27) after onset
in 27 patients. Normal ERG recordings (group 1) were present
in 20 patients (74%), 2 years (0.1–21) after disease onset. We
found group 2 ERGs in 4 patients (15%) with 1 year (0.1–3.5)
after onset, and group 3 recordings in 3 patients (11%) with
18 years (6–27) after onset. Follow-up for ERG recordings
was available in 21 patients. In 4 of these patients progressed
from group 1 to group 2 (median time, 8 (7–16) years), 2
patients progressed from group 2 to group 3 (within 2 and
3 years), and 1 patient progressed from group 1 to group 3
in 6 years. In 17 patients, color vision was tested. In 15 pa-
tients (79%), abnormalities were noticed, red-green defects in
14 patients, and a blue-yellow defect in 1 patient.
Various imaging modalities of patient 28 and patient 21 are
depicted respectively in Figs. 2 and 3.
Genetic characteristics
Overall, genetic analysis was not performed at first visit, but
with a median delay of 5 years (range, 0–30) after the first
visit. An overview of ABCA4 variants in our cohort is de-
scribed in Table 2.
Variants in the ABCA4 gene were identified in 59 of 62
alleles (95%). Three variants were found in one patient, two
ABCA4 variants in 27, and one variant in three. In total, 32
distinct variants were detected. The majority of the patients
(65%) carried at least one variant with a severe effect on
ABCA4 function (Table 2, in italics).
Discussion
A lack of obvious fundus abnormalities left a high number of
children with STGD1 disease without the correct diagnosis.
Instead, these patients underwent unnecessary investigations,
such as psychic evaluations, brain MRIs or CTs, and lumbar
punctures. Many of these children were treated for mental
illness and/or amblyopia with pointless and possibly harmful
treatments, including years of occlusion therapy.
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In patients with adult-onset STGD1, initial ophthalmoscop-
ic features typically include yellow-white flecks and central
macular atrophy, and cases without fundus abnormalities have
not been described [6]. In young children, the clinical presen-
tation can be confusing for the general ophthalmologist.
Fujinami et al. [7] noticed that one third of their child cohort
(< 17 years) initially had a normal fundus appearance.
Lambertus et al. [5] described a cohort of 41 STGD1 patients
younger than 10 years, and 10 of these patients (24%) also did
not have fundus abnormalities. These studies show that the
absence of readily observable fundus abnormalities in young
STGD1 patients is not an isolated finding, but a relative com-
mon part of the clinical spectrum.
Recently, Khan et al. reported the earliest features of
ABCA4-associated retinopathy [20]. In their study, they in-
cluded eight children (six prospectively) to describe their oph-
thalmologic features. At the first visit, four children were
asymptomatic and four had complaints of visual decline. In
six out of eight children, the central macula appeared normal
or had an altered foveal reflex. This is similar to the findings in
our study. In contrast, their study focused on the (most pro-
spectively) appearance of abnormalities in ABCA4-related
dystrophy even if they were asymptomatic. Our study is fo-
cused, retrospectively, on STGD1 patients initially without
fundus abnormalities, despite having visual complaints.
Besides the natural course of this phenotype, we describe the
reasons of delay in diagnoses and to find similarities within
this group of patients in order to provide recommendations for
ophthalmologists in general. Therefore, this study is a contri-
bution from another point of view of children with STGD1
which initially present without fundus abnormalities.
In our cohort, when fundus abnormalities did occur, these
were often not the typical yellowish flecks but rather RPE
alterations, often in a bull’s eye pattern. A hypothesis for the
absence of typical fundus flecks may lie in the relative high
pathogenicity of ABCA4 variants. As the majority of our co-
hort (65%) carried at least one severe variant, there may be
little ABCA4 function left in these patients, leading to a very
early manifestation of the disease. The buildup of toxic A2E in
RPE cells develops rapidly, thereby causing early cell death
without the opportunity for lipofuscin to accumulate and sub-
sequent fleck formation.
Blocking of the choroidal vessels on FA resulting a dark or
silent choroid is frequently used as a diagnostic marker for
STGD1. The prevalence of this FA finding in STGD1 patients
has been described in up to 86% of patients [21]. A dark
Follow-up after first ophthalmic consultation (years)
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Fig. 1 Course of the best-corrected visual acuity (BCVA) in logMAR in
ten patients. The visual acuity varies greatly during the first 5 years after
first ophthalmic consultation. LogMAR 0 = 20/20 Snellen, LogMAR
0.5 = 20/63 Snellen, LogMAR 1.00 = 20/200 Snellen, LogMAR 1.50 ≈
20/630 Snellen, LogMAR 2.00 = 20/2000 Snellen. Each patient (ID =
identification) is shown in a different color
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Fig. 2 Three-and-a-half year follow-up in patient ID28. Age at onset at
6.5 years, 1 year later the fundus auto-fluorescence showed a perifoveal
ring of hyper-fluorescence (A2), and on OCT, a discrete thickening of the
external limiting membrane can be seen (A3, red arrow). Only 6 months
later, a subtle hyper-fluorescent perifoveal lesion developed as shown in
B2, red arrow. Over time, the hyper-fluorescent flecks become more
visible on autofluorescence imaging. In addition, the flecks became no-
ticeable on color fundus photographs. The thickened external limiting
membrane remained present during the entire follow-up time (red arrows
A3, C3, D3, E3, F3, H3)
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choroid was present in 65% in our relatively small cohort. A
correlation has been described between the presence of
yellow-white fundus flecks and the appearance of dark cho-
roid [9, 22], which might account for the relatively low per-
centage of patients with a dark choroid in this cohort. FAF
imaging is a relatively new modality that may be used to
identify early and subtle lipofuscin [23]. In addition, a thick-
ened ELM on OCT may also serve as an early marker for
STGD1 [24]. However, in the study of Lee et al., this distinct
ELM thickening was described to occur in all (26/26) cases. In
our cohort, only 2/23 cases with performed OCT (0.5 and
1 year after disease onset) were observed to have this feature.
The delay of performing an OCT (mean, 9 years after disease
onset), could be an explanation of the difference in the appear-
ance of ELM thickening in both cohorts. Abnormal color vi-
sion was observed in 79% of our STGD1 patients, which
corresponds with the previously reported percentages [25].
Fluctuation of visual acuity in 10/31 children in the first
5 years of ophthalmic consultation suggests that visual acuity
is an ambiguous symptom at early stages of STGD1. This
could be explained by lowered reading performance due to
ring scotomas that allow for good visual acuity, but cause
visual field impairment. [26]
Although STGD1 is the most common juvenile macu-
lar dystrophy, it remains a relatively rare disorder.
Clinicians in a general ophthalmic practice may lack the
exper ience to ident i fy and interpre t the subt le
abnormalities in these young children. When we take into
account the relative difficulty associated with the ophthal-
mic examination of (very) young children, the high num-
ber of misdiagnoses in the early-onset STGD1 patient
group may not come as a surprise. Therefore, we want
to make ophthalmologists aware of early findings in
STGD1, especially appearing in children. First, visual
acuity often fluctuates in these patients which should not
automatically rule out the possibility of a photoreceptor
disease. Second, a fundus photograph can be helpful in
discerning very subtle fundus abnormalities and may be
useful in follow-up. Third, non-invasive investigations
such as OCT (thickening of the ELM), FAF (subtle
lipofuscin accumulation), and color vision tests may help
in the diagnostic process. FA is invasive, apart from the
oral variant, but may also be less helpful in patients with-
out fundus abnormalities in the light of the relatively low
percentage of dark choroids in these patients.
In children with visual disturbances, retinal dystrophies
should be considered and ruled out when possible, even in
the absence of fundus abnormalities on ophthalmoscopy, be-
cause STGD1 may be a cause of low vision in normal fundus.
Instead of wait and see, we would recommend referring these
children to a tertiary ophthalmic center and performing OCT
and FAF to define early findings of STGD1. In addition, early
identification may prove important in the light of emerging
therapeutic options.
Fig. 3 Multimodal imaging in
ID21 at age 25, 15 years after the
first symptoms. The visual acuity
is now 20/1000 Snellen OU.
Color fundus photography (a)
shows attenuated retinal vessels
(especially the veins), para-
arteriolar pigmentation, and dif-
fuse chorioretinal atrophy. The
fundus autofluorescence (b)
shows widespread
hypofluorescence, especially at
the macula, indicative of RPE cell
loss. The fluorescence angiogram
(c) shows widespread granular
hyperfluorescent lesions as result
of RPE damage, and on the OCT
(d), loss of the outer retinal layers,
as well as the choriocapillaris, can
readily be observed
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